Brought to you by 
Cancer Prevention grants option to Sucampo for FAP therapy
26 Sep 2017
Executive Summary
Cancer Prevention Pharmaceuticals Inc. granted Sucampo Pharmaceuticals Inc. an option to license exclusive North American development and commercialization rights to CPP-1X/sulindac for familial adenomatous polyposis (FAP).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cancer Prevention grants option to Sucampo for FAP therapy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice